Printer Friendly

ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC

ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC
 LONDON, March 19 /PRNewswire/ -- Orthofix International N.V. ("Orthofix"), a leading producer of external fixation devices used in fracture treatment, limb lengthening and bone reconstruction, has filed a registration statement with the Securities and Exchange Commission (SEC) in connection with a proposed public offering in the United States of an aggregate of 2,600,000 common shares and a concurrent offering outside the United States of an aggregate of 650,000 common shares. Of the 3,250,000 common shares being offered, 2,079,914 are being sold by Orthofix and 1,170,086 are being sold by certain of its shareholders. It is anticipated that the proposed sale to the public will commence in late April 1992.
 It is currently estimated that the initial public offering price for the common shares will be between $14 and $16 per share. The net proceeds of the offering to Orthofix will primarily be used to acquire licenses, products or


companies in the trauma, orthopedic and related medical fields, to fund research and development and for working capital and general corporate purposes.
 Alex. Brown & Sons Inc. and Oppenheimer & Co. Inc. are the lead managers of the U.S. and international offerings.
 A registration statement relating to these securities has been filed with the U.S. SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any state.
 No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date. An indication of interest in response to this announcement will involve no obligation or commitment of any kind.
 -0- 3/19/92
 /CONTACT: Robert Gaines Cooper, Edgar Wallner or Peter Clarke of Orthofix International N.V., 44-491-579600, or (fax) 44-491-579750/ CO: Orthofix International N.V. ST: IN: HEA MTC SU: OFR


EH-JL -- SD004 -- 9530 03/19/92 09:05 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:418
Previous Article:AGOURON PHARMACEUTICALS NAMES FORMER PRESIDENT OF MERCK INTERNATIONAL TO BOARD
Next Article:AMC GEARS UP FOR THE ACADEMY AWARDS
Topics:


Related Articles
ORTHOFIX INTERNATIONAL N.V. FILES REGISTRATION STATEMENT WITH THE SEC
Orthofix Announces Distribution Agreement with Sulzer
Orthofix Enters Distribution Agreement With Sofamor Danek Group
Orthofix Receives FDA Approval to Modify Labeling on Bone Growth Stimulators
Study Shows Bone Cells Can Be Grown With Electrical Stimulation, and That VEGF Protein May Be Part of the Biological Mechanism of Action.
Orthofix Announces Agreements With Aetna U.S. Healthcare and Empire Blue Cross & Blue Shield For Covering its Bone Growth Stimulators.
Orthofix Appoints Ernst & Young LLP as New Independent Accountants.
Orthofix to Present at UBS Global Life Sciences Conference.
Orthofix International to Present at U.S. Bancorp Piper Jaffray Health Care Conference.
Orthofix Vascular Patents Confirmed by U.S. Patent Office.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters